Breaking News, Collaborations & Alliances

Tevogen Completes Tech Transfer to CDMO BioCentriq

Reaches commercial manufacturing readiness milestone for its investigational COVID-19 therapy TVGN-489.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tevogen Bio has completed the technology transfer of its investigational COVID-19 therapy TVGN-489 to BioCentriq, its clinical manufacturing partner, representing a major milestone in achieving commercial manufacturing readiness. TVGN-489 consists of Allogeneic COVID-19 Specific Cytotoxic CD8+ T Lymphocytes (CTLs), which are specifically designed for the treatment of high-risk patients who are at-risk of breakthrough infections and progressing to severe COVID-19.   “The troubling emergence of br...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters